NASDAQ:NITE - Nightstar Therapeutics plc
$15.00
 $0.26
+1.76%
1:55PM EDT
2019-02-15
Nightstar Therapeutics PLC, formerly Nightstar Therapeutics Limited, is a clinical-stage gene therapy company. The Company is focused on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases that would otherwise progress to blindness. The Company is developing a pipeline of proprietary product candidates that are designed to substantially modify or halt the progression of inherited retinal diseases. The Companys lead product candidate, NSR-REP1, for the treatment of choroideremia, or CHM, is entering Phase III clinical development. The Company is also conducting a Phase I/II clinical trial with its second product candidate, NSR-RPGR, for the treatment of X-linked retinitis pigmentosa, or XLRP. The Companys third product candidate, NSR-BEST1, is in preclinical development for the treatment of Best vitelliform macular dystrophy, or Best disease.The Companys NSR-REP1 is comprised of an AAV2 vector containing recombinant human complementary DNA, or cDNA, which is designed to produce REP1 inside the eye. NSR-REP1 is comprised of a standard AAV vector combined with the human REP1 cDNA and a woodchuck hepatitis post-transcriptional regulatory element, or WPRE, sequence. Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  NITE     avg for
industry  
  avg for
sector  
42 stocks weight:  72. 13   0. 00   0. 00  
42 stocks rank:  2. 28 K 1. 86 K 1. 09 K
# analyst opinions:  10. 00   14. 92   14. 43  
mean recommendation:  1. 60   1. 91   1. 93  

quick ratio:  7. 42   5. 37   1. 81  
current ratio:  7. 67   5. 69   2. 19  

target price low:  21. 00   88. 97   117. 82  
target price avg:  32. 90   115. 19   141. 96  
target price high:  42. 00   143. 40   163. 16  
1-yr high:  27. 78   124. 30   142. 77  
last close:  14. 74   101. 85   127. 84  
50-day avg:  13. 11   98. 27   122. 46  
200-day avg:  15. 88   99. 72   122. 70  
1-yr low:  10. 10   78. 19   100. 16  
volume:  12. 55 K 2. 38 M 4. 64 M
50-day avg volume:  70. 78 K 3. 31 M 4. 94 M
200-day avg volume:  107. 14 K 3. 23 M 4. 28 M

1-day return:  4. 91 % 0. 22 % 0. 48 %
this week return:  4. 24 % 1. 77 % 2. 01 %
12-wk return:  -3. 72 % 6. 56 % 3. 33 %
52-wk return:  34. 97 % -2. 23 % 14. 35 %

enterprise value (EV):  315. 68 M 55. 17 B 104. 51 B
market cap:  493. 56 M 49. 01 B 96. 46 B
EBITDA:  -44. 62 M 4. 82 B 7. 18 B
enterprise multiple (EV/EBITDA):  -7. 08   -91. 79   2. 29  
total debt:  0. 00   13. 73 B 16. 57 B
net income (common):  -42. 26 M 2. 37 B 3. 58 B

shares outstanding:  33. 48 M 607. 99 M 1. 22 B
shares:  18. 62 M 605. 53 M 1. 15 B
shares short:  425. 48 K 11. 62 M 12. 55 M
shares short prior month:  606. 37 K 11. 95 M 13. 44 M
short ratio:  9. 12   4. 82   3. 10  
total cash/share:  3. 49   12. 02   11. 46  
total cash:  100. 77 M 7. 41 B 7. 37 B
operating cash flow:  -39. 05 M 164. 74 M 3. 04 B

book value:  3. 45   14. 43   28. 26  
price/book:  4. 27   -1. 57   -2. 97  
operating margins:  0. 00 % -458. 01 % -642. 83 %
EBITDA margins:  0. 00 % 13. 81 % 22. 47 %
profit margins:  0. 00 % 6. 57 % 9. 92 %
gross margins:  0. 00 % 49. 33 % 54. 53 %

1-yr max volatility:  18. 44 % --- ---
1-yr mean volatility:  0. 22 % 0. 01 % 0. 06 %

1-yr EPS:  -1. 69   3. 03   4. 09  
forward EPS:  -1. 64   4. 33   6. 99  
P/E:  -8. 73   6. 11   26. 91  
forward P/E:  -8. 99   8. 38   10. 48  
PE/G:  1. 46   0. 37   5. 61  
growth:  -5. 99 % 683. 72 % 104. 79 %
earnings high:  -0. 25   1. 27   1. 66  
earnings avg:  -0. 37   1. 01   1. 53  
earnings low:  -0. 49   0. 76   1. 40  
revenue high:  -0. 00   2. 86 B 11. 19 B
revenue avg:  -0. 00   2. 78 B 10. 84 B
revenue low:  -0. 00   2. 67 B 10. 64 B
return on assets:  -22. 47 % -3. 27 % 3. 81 %
return on equity:  -38. 86 % 107. 48 % 27. 82 %

beta (1yr vs S&P500):  0. 64   1. 21   0. 93  
sharpe (1yr):  0. 73   0. 06   0. 98  

held % insiders:  41. 01 % 6. 46 % 3. 21 %
held % institutions:  50. 78 % 79. 10 % 70. 01 %

Research more with google or yahoo!
the data below are updated and published after 9pm EDT each trading day

2019-02-14 : NITE
.     + 2.15 =          2.15 :: INITIAL WEIGHT
.  + 443.316 =       445.466 :: inverse volume-to-price addition
.  + 314.711 =       760.178 :: spline projection addition
.  - 166.434 =       593.744 :: poor performance penalty
.    x 1.108 =       658.029 :: one-year gains+dividend factor
.    x 7.402 =      4870.927 :: 13 weeks' performance factor
.    x 1.492 =      7269.804 :: industry recommendation factor
.    x 2.982 =     21681.955 :: symbol recommendation factor
.    x 0.998 =      21633.24 :: return on assets factor
.    x 0.996 =     21549.169 :: return on equity factor
.    x 2.652 =     57155.685 :: current ratio factor
.    x 1.075 =     61443.458 :: quick ratio factor
.    x 1.053 =     64724.467 :: short ratio factor
.    x 2.043 =    132215.066 :: price-to-book factor
.    x 1.089 =    143929.508 :: 5-day avg > 50-day avg
.    x 2.118 =    304911.113 :: P/E weight
.     x 0.91 =    277523.828 :: PE/G factor
.    x 1.635 =    453742.465 :: beta factor
.    x 0.727 =     329682.55 :: sharpe factor
.    x 1.694 =    558445.268 :: target low factor
.     x 1.37 =    765063.452 :: target mean factor
.    x 1.136 =    869106.158 :: target high factor
.    x 1.066 =    926130.652 :: industry 12-weeks return
.     x 0.99 =    916420.794 :: "drift" penalty 5 days ago
.      x 1.0 =    916119.215 :: overall "drift" factor
.    x 0.999 =    915492.003 :: largest single-day jump factor
.     x 0.41 =     375201.64 :: low price factor
.      x 1.0 =    375226.825 :: factor hist industry gain for week 06
.   cubeRoot =        72.127 :: reduced for readability
.                     72.127 :: FINAL WEIGHT for NASDAQ:NITE


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org